MacroGenics, Inc. (MGNX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Arbutus Biopharma Corp.

Arcutis Biotherapeutics, Inc.

Coherus BioSciences, Inc.

MacroGenics, Inc.

Nurix Therapeutics, Inc.

ARS Pharmaceuticals, Inc.

Erasca, Inc.

Oric Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

Cullinan Therapeutics, Inc.

Icosavax, Inc.

Why is MacroGenics, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of 10.53% and Operating profit at 5.74% over the last 5 years

The company has declared negative results in Mar'2025 after 2 consecutive positive quarters

NET PROFIT(HY) At USD -19.43 MM has Grown at -3,112.25%
OPERATING CASH FLOW(Y) Lowest at USD -162.47 MM
NET SALES(HY) At USD 95.08 MM has Grown at -21.75%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 97.97%, its profits have risen by 22.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is MacroGenics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

MacroGenics, Inc.

186.71%

-0.37

97.92%

S&P 500

27.93%

0.62

19.30%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.53%

EBIT Growth (5y)

5.74%

EBIT to Interest (avg)

-128.79

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.88

Sales to Capital Employed (avg)

0.94

Tax Ratio

1.72%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.94

EV to EBIT

-1.11

EV to EBITDA

-1.19

EV to Capital Employed

-31.51

EV to Sales

0.99

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-113.26%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET SALES(HY)

At USD 62 MM has Grown at 90.51%

NET PROFIT(HY)

Higher at USD -50.93 MM

RAW MATERIAL COST(Y)

Fallen by -0.83% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -231.19 %

-27What is not working for the Company

NET SALES(Q)

At USD 20.77 MM has Fallen at -44.41%

PRE-TAX PROFIT(Q)

At USD -36.77 MM has Fallen at -95.37%

NET PROFIT(Q)

At USD -36.77 MM has Fallen at -97.13%

ROCE(HY)

Lowest at -140.27%

CASH AND EQV(HY)

Lowest at USD 344.14 MM

INTEREST(Q)

Highest at USD 4.89 MM

Here's what is working for MacroGenics, Inc.

Debt-Equity Ratio

Lowest at -231.19 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -0.83% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for MacroGenics, Inc.

Net Sales

At USD 20.77 MM has Fallen at -44.41%

over average net sales of the previous four periods of USD 37.37 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -36.77 MM has Fallen at -95.37%

over average net sales of the previous four periods of USD -18.82 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -36.77 MM has Fallen at -97.13%

over average net sales of the previous four periods of USD -18.66 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 4.89 MM has Grown at 14.44%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest

Highest at USD 4.89 MM

in the last five periods and Increased by 14.44% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 344.14 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents